Quick Answer
Kalaris Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $98.05 million for the year ending 2025.
- Kalaris Therapeutics, Inc. showed an increase of +5,882.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Kalaris Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $168.60 million | Q2 2020: $78.27 million | Q3 2020: $142.25 million | Q1 2021: $168.65 million | Q2 2021: $225.45 million | Q3 2021: $243.19 million | Q1 2022: $100.21 million | Q2 2022: $71.09 million | Q3 2022: $123.83 million | Q1 2023: $115.70 million | Q2 2023: $196.95 million | Q3 2023: $95.63 million | Q1 2024: $5.23 million | Q2 2024: $6.24 million | Q3 2024: $1.91 million | Q1 2025: $100.97 million | Q2 2025: $88.43 million | Q3 2025: $42.39 million.
- Over the full 7 years of available data (2019 to 2025), Kalaris Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 60.5%.
- Historical annual values: Fiscal year 2025: $98.05 million | Fiscal year 2024: $1.64 million | Fiscal year 2023: $90.12 million | Fiscal year 2022: $106.09 million | Fiscal year 2021: $201.66 million | Fiscal year 2020: $122.66 million | Fiscal year 2019: $61.08 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: